Developmental pharmacogenomics
- 15 February 2011
- journal article
- review article
- Published by Wiley in Pediatric Anesthesia
- Vol. 21 (3) , 255-265
Abstract
Summary: Interindividual variability in the disposition and action associated with similar doses of a given medication is an inherent characteristic of both adult and pediatric populations. Genotype–phenotype relationships in infants and children must take into account the role that ontogeny plays in producing variability in both pharmacokinetics and pharmacodynamics. This review explores pharmacogenomics in the context of ontogeny and relates these to the expression of drug‐metabolizing enzymes and transporters and the consequent effect on the exposure–response relationship in the early years of life.Keywords
This publication has 90 references indexed in Scilit:
- Thiopurine pathwayPharmacogenetics and Genomics, 2010
- Impact of the CYP2C19*17 Allele on the Pharmacokinetics of Omeprazole and Pantoprazole in Children: Evidence for a Differential EffectDrug Metabolism and Disposition, 2010
- Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical EffectsJournal of Clinical Oncology, 2009
- A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin DosePLOS Genetics, 2009
- Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic LeukemiaJAMA, 2009
- A Genome-Wide Association Study Identifies Novel and Functionally Related Susceptibility Loci for Kawasaki DiseasePLOS Genetics, 2009
- Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel diseaseNature Genetics, 2008
- Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 genePharmacogenetics and Genomics, 2008
- Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthmaNature, 2007
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClinical Pharmacology & Therapeutics, 2006